Core Viewpoint - Rosen Law Firm is reminding purchasers of MoonLake Immunotherapeutics common stock of the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the class period from March 10, 2024, to September 29, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased MoonLake common stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must move the Court to serve as lead plaintiff by December 15, 2025 [3]. - The lawsuit claims that the defendants made false and misleading statements regarding the clinical benefits of their product SLK compared to traditional monoclonal antibodies, which led to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

MLTX DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 29, 2025 10:14 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclu ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) --  Fa ...

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that during the class period, the defendants made false and misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and has recovered hundreds of millions for investors over the years [4].

Core Points - Rosen Law Firm is reminding purchasers of MoonLake Immunotherapeutics common stock about the December 15, 2025 lead plaintiff deadline for a class action lawsuit [1][3] - Investors who purchased shares during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Company Details - The complaint alleges that during the Class Period, defendants made false and misleading statements regarding the efficacy of SLK compared to traditional monoclonal antibodies, specifically concerning the molecular targets and clinical benefits [5] - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading information provided by the defendants [5] Legal Process - To join the class action, investors can submit a form or contact the law firm directly for more information [3][6] - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1] Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements since 2013 [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The complaint alleges that during the Class Period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies [5] - Specific claims include that SLK and BIMZELX target the same inflammatory cytokines, and that SLK's unique structure does not provide superior clinical benefits [5] - The lawsuit claims that when the true information became public, investors suffered damages due to the misleading statements [5]

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 15, 2025 deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - The class period for the MoonLake Immunotherapeutics securities class action is from March 10, 2024, to September 29, 2025 [1]. - Investors who purchased common stock during this period may be eligible for compensation without any upfront fees through a contingency fee arrangement [2]. - To participate in the class action, investors must apply by December 15, 2025, to serve as lead plaintiff, representing other class members [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant settlements for investors [4]. - The firm has been recognized for its achievements, including being ranked No. 1 for securities class action settlements in 2017 and recovering over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The complaint alleges that during the class period, MoonLake Immunotherapeutics made false or misleading statements regarding the efficacy of its product SLK compared to traditional monoclonal antibodies, specifically BIMZELX [5]. - Key points of contention include claims about the molecular targets and clinical benefits of SLK, which were allegedly overstated, leading to investor damages when the truth was revealed [5].

Core Viewpoint - MoonLake Immunotherapeutics has faced a significant decline in share price, dropping nearly 90% in one day due to disappointing Phase 3 trial results for its drug candidate sonelokimab (SLK) [1][5]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing SLK, which is intended to treat moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease [3]. Legal Issues - A securities fraud class action lawsuit has been filed against MoonLake in the U.S. District Court for the Southern District of New York, alleging that the company and certain executives made materially false and misleading statements regarding SLK's clinical prospects [2][4]. - The lawsuit claims that MoonLake exaggerated SLK's benefits over competitors, particularly in relation to its unique "Nanobody" structure, which was presented as a major competitive advantage [4][6]. Trial Results - The VELA Phase 3 trials, particularly VELA-2, did not meet their primary endpoint, leading to a significant drop in stock price from $61.99 to $6.24, a decrease of $55.75 per share [5]. - Analysts noted that the efficacy results from the successful trial were substantially lower than those achieved by the competitor drug BIMZELX, which shares the same molecular targets [4][6]. Investor Impact - The decline in stock price has prompted Hagens Berman, a plaintiffs' rights firm, to investigate claims of misleading information that may have artificially inflated the stock price during the class period from March 10, 2024, to September 29, 2025 [2][6].

Core Viewpoint - MoonLake Immunotherapeutics is facing a class action lawsuit due to allegations of misleading investors about the efficacy of its drug candidate SLK, particularly in comparison to the FDA-approved drug BIMZELX [1][3]. Company Overview - MoonLake Immunotherapeutics (MLTX) is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), with a particular emphasis on dermatology and rheumatology [1]. Class Action Details - The class period for the lawsuit is defined as March 10, 2024, to September 29, 2025 [1]. - The lawsuit was filed on behalf of all investors who purchased or acquired MoonLake's common stock during this period [1]. Allegations - The complaint outlines several key allegations: - SLK and BIMZELX share the same molecular targets (IL-17A and IL-17F) [3]. - SLK's Nanobody structure does not provide a superior clinical benefit over BIMZELX's monoclonal structure [3]. - The supposed increased tissue penetration of SLK does not translate to clinical efficacy [3]. - Defendants lacked a reasonable basis for their positive statements regarding SLK's superiority [3]. Stock Price Impact - Following the announcement of the week-16 results from the Phase 3 VELA program on September 28, 2025, which showed SLK's failure to demonstrate competitive efficacy relative to BIMZELX, MoonLake's stock price dropped significantly [4]. - The stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over traditional monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 20 years of experience [4].